Resumen
Aims The ability of the right ventricle (RV) to adapt to increased afterload is the major determinant of survival in patients with pulmonary hypertension (PH). In this study, we explored the effect of genetic background on RV adaptation and survival in a rat model of severe pulmonary arterial hypertension (PAH). Methods and results PH was induced by a single injection of SU5416 (SU) in age-matched Sprague Dawley (SD) or Fischer rats, followed by a 3-week exposure to chronic hypoxia (SUHx). SD and Fischer rats exhibited similar elevations in RV systolic pressure, number of occlusive pulmonary vascular lesions, and RV hypertrophy (RV/LV+S) in response to SUHx. However, no Fischer rats survived beyond 7 weeks compared with complete survival for SD rats. This high early mortality of Fischer rats was associated with significantly greater RV dilatation and reduced ejection fraction, cardiac output, and exercise capacity at 4 weeks post-SU. Moreover, microarray analysis revealed that over 300 genes were uniquely regulated in the RV in the severe PAH model in the Fischer compared with SD rats, mainly related to angiogenesis and vascular homoeostasis, fatty acid metabolism, and innate immunity. A focused polymerase chain reaction array confirmed down-regulation of angiogenic genes in the Fischer compared with SD RV. Furthermore, Fischer rats demonstrated significantly lower RV capillary density compared with SD rats in response to SUHx. Conclusion Fischer rats are prone to develop RV failure in response to increased afterload. Moreover, the high mortality in the SUHx model of severe PAH was caused by a failure of RV adaptation associated with lack of adequate microvascular angiogenesis, together with metabolic and immunological responses in the hypertrophied RV.
Idioma original | English |
---|---|
Páginas (desde-hasta) | 788-799 |
Número de páginas | 12 |
Publicación | Cardiovascular Research |
Volumen | 115 |
N.º | 4 |
DOI | |
Estado | Published - mar. 15 2019 |
Publicado de forma externa | Sí |
Nota bibliográfica
Funding Information:This work was funded by a grant from the Canadian Health Research Institute (CIHR; Foundation grant: FDN-143291). Additional funding was provided by an unrestricted grant from Northern Therapeutics Inc. (NT). K.R.C. is a recipient of Research Fellowship from Heart and Stroke Foundation of Canada and Scholar award from Canadian Vascular Network and CIHR.
Publisher Copyright:
© The Author(s) 2018. Published by Oxford University Press on behalf of the European Society of Cardiology.
ASJC Scopus Subject Areas
- Physiology
- Cardiology and Cardiovascular Medicine
- Physiology (medical)